Skip to main content
. 2013 Oct 2;8:3757–3768. doi: 10.2147/IJN.S51353

Figure 3.

Figure 3

Tumor growth rate and survival time for the different groups: Lipiodol® (Guerbet, Villepinte, France) (Group A, 16), nanoplex/Lipiodol (Group B, 25), nanoplex-p53/Lipiodol (Group C, 30), nanoplex-Rb/Lipiodol (Group D, 25), and nanoplex-(p53+Rb)/Lipiodol (Group E, 25).

Notes: * Δ, ▲, and ✰ represent significant difference from Groups A, B, C, and D, respectively, as calculated with one-way analysis of variance and Fisher’s least significant difference multiple comparison test.

Data for A, B, and C from11.